Skip to main content

Unsupervised Hierarchical Clustering of Surface Antigen Expression to Identify Patients with Normal Karyotype AML with Distinct Disease Characteristics and Poor Outcome

Conference Correspondent - ASCO 2017 - Acute Myeloid Leukemia

There is limited understanding of the biologic and prognostic implications of surface antigen expression patterns in patients with normal karyotype acute myeloid leukemia (AML). Researchers sought to understand the relationship between surface antigen expression and molecular disease features.

The diagnostic antigen expression patterns of mononuclear cells in the bone marrow of 111 patients with normal karyotype AML were assessed using a standard flow cytometric panel. All patients received stem-cell transplantation after induction therapy. The median follow-up was 3.3 years. Hierarchical clustering of surface antigens revealed 4 distinct clusters of surface antigens. Cluster 1 (n = 36) had higher expression of immature surface antigens; cluster 2 (n = 31) had higher expression of surface antigens of thrombocytic or erythroid origin; cluster 3 (n = 24) had higher expression of monocytic surface antigens; and cluster 4 (n = 20) had higher expression of granulocytic surface antigens.

All 4 clusters showed distinct clinical and molecular features. Most notably, patients with high expression of immature surface antigens had a higher cumulative incidence of relapse at 1 year (41% vs 15%; P = 0.002) and shorter event-free survival at 1 year (50% vs 69%; P = 0.02). In multivariate analysis, differences persisted after adjustment for FLT3 mutation status, age, and disease status at the time of stem-cell transplant.

The researchers identified a relationship between easily accessible surface antigen expression patterns at diagnosis, molecular disease features, and aggressiveness of the normal karyotype AML phenotype.

Jentzsch M, et al. ASCO Abstract 7042.

Related Items
Differentiation Syndrome Associated with Enasidenib, a Selective Inhibitor of mIDH2
Conference Correspondent published on June 5, 2017 in ASCO 2017 - Acute Myeloid Leukemia
Outcomes with Lower-Intensity Therapy in TP53-Mutated AML
Conference Correspondent published on June 5, 2017 in ASCO 2017 - Acute Myeloid Leukemia
Enasidenib in Mutant-IDH2 Relapsed or Refractory AML: Results of a Phase 1 Dose-Escalation and Expansion Study
Conference Correspondent published on June 5, 2017 in ASCO 2017 - Acute Myeloid Leukemia
Using a Synthetic Control Arm to Establish Early End Points as Indicators of Overall Survival in Acute Myeloid Leukemia
Conference Correspondent published on June 5, 2017 in ASCO 2017 - Acute Myeloid Leukemia
Sorafenib plus 5-Azacytidine in Older, Untreated FLT3-ITD–Positive Patients with Acute Myeloid Leukemia
Conference Correspondent published on June 5, 2017 in ASCO 2017 - Acute Myeloid Leukemia
Last modified: August 30, 2021